A novel antimetabolite: TAS-102 for metastatic colorectal cancer

被引：8
|
作者：
Miyamoto, Yuji [1 ,2 ]
Lenz, Heinz-Josef [2 ]
Baba, Hideo [1 ]
机构：
[1] Kumamoto Univ, Dept Surg Gastroenterol, Grad Sch Med Sci, 1-1-1 Honjo, Kumamoto 8608556, Japan
[2] Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Div Med Oncol, Los Angeles, CA 90033 USA
来源：
EXPERT REVIEW OF CLINICAL PHARMACOLOGY | 2016年 / 9卷 / 03期
关键词：
refractory; salvage line; metastatic colorectal cancer; TAS-102; phase III; intolerant; chemotherapy; ORAL CHEMOTHERAPEUTIC-AGENT; RANDOMIZED PHASE-III; THYMIDINE KINASE 1; SOLID TUMORS; THYMIDYLATE SYNTHASE; FLUORINATED PYRIMIDINES; 1ST-LINE TREATMENT; ANTITUMOR-ACTIVITY; COMBINATION ANTIMETABOLITE; SYNERGISTIC INTERACTION;
D O I：
10.1586/17512433.2016.1133285
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
TAS-102 is a new oral anti-tumor drug, composed of a thymidine-based nucleoside analog (trifluridine: FTD) and a thymidine phosphorylase inhibitor (tipiracil hydrochloride: TPI). TAS-102 has been shown to significantly improve overall survival and progression-free survival in patients with refractory metastatic colorectal cancer (mCRC) in placebo-controlled randomized phase II and III trials. The current review summarizes mechanisms of action, pharmacokinetics/dynamics and preclinical and clinical data of TAS-102 in colorectal cancer. TAS-102 is a new salvage-line treatment option for patients with mCRC. TAS-102 is well tolerated and has great potential in future clinical drug combination therapies.
引用
收藏
页码：355 / 365
页数：11
相关论文
共 50 条
  • [21] Sidedness of the primary tumor on the effect of TAS-102 for refractory metastatic colorectal cancer
    Ueda, S.
    Tsuboguchi, Y.
    Nakatani, Y.
    Tsuya, A.
    Nishina, S-I.
    Akiyoshi, K.
    Okazaki, S.
    Tokunaga, S.
    Daga, H.
    [J]. ANNALS OF ONCOLOGY, 2018, 29
  • [22] Usefulness of TAS-102 as Third-line Chemotherapy for Metastatic Colorectal Cancer
    Kawahara, Hidejiro
    Mouri, Takashi
    Ishida, Kota
    Matsumoto, Nori
    Akiba, Tadashi
    Yanaga, Katsuhiko
    [J]. ANTICANCER RESEARCH, 2018, 38 (04) : 2419 - 2422
  • [23] TAS-102 (Lonsurf) for the Treatment of Metastatic Colorectal Cancer. A Concise Review
    Zaniboni, Alberto
    Bertocchi, Paola
    Barni, Sandro
    Petrelli, Fausto
    [J]. Clinical Colorectal Cancer, 2016, 15 (04) : 292 - 297
  • [24] Effectiveness of TAS-102 in patients with metastatic colorectal cancer in a single comprehensive cancer center
    Sales, C.
    Juliao, I.
    Rosinha, A.
    Marques, D.
    Carneiro, F.
    Faustino, C.
    Machado, M.
    Ferreira, P.
    Fragoso, M.
    Sousa, N.
    [J]. ANNALS OF ONCOLOGY, 2018, 29 : 79 - 79
  • [25] Efficacy and safety of regorafenib compared to TAS-102 for refractory metastatic colorectal cancer
    Abrahao, Ana Beatriz Kinupe
    Ko, Yoo-Joung
    Chan, Kelvin K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [26] Usefulness of TAS-102 as Third-line Chemotherapy for Metastatic Colorectal Cancer
    Kawahara, Hidejiro
    Yanaga, Katsuhiko
    [J]. CANCER SCIENCE, 2018, 109 : 601 - 601
  • [27] Colorectal Cancer TAS-102 effective with refractory Recurrence
    Franke, Katharina
    [J]. ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2015, 53 (10): : 1144 - 1144
  • [28] TAS-102 in refractory colorectal cancer: caution is needed
    Sobrero, Alberto
    [J]. LANCET ONCOLOGY, 2012, 13 (10): : 959 - 961
  • [29] A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells
    Emura, T
    Murakami, Y
    Nakagawa, F
    Fukushima, M
    Kitazato, K
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2004, 13 (04) : 545 - 549
  • [30] A systematic review of observational studies of trifluridine/tipiracil (TAS-102) for metastatic colorectal cancer
    Andersen, Stig E.
    Andersen, Ida B.
    Jensen, Benny V.
    Pfeiffer, Per
    Ota, Takayo
    Larsen, Jim S.
    [J]. ACTA ONCOLOGICA, 2019, 58 (08) : 1149 - 1157
12345